Pfizer's third-generation ALK inhibitor Borina(R) successfully held the launch meeting

ALK patient education support project launched simultaneously

Guangzhou, Aug.

Zhenke Peng, President of Pfizer Biopharmaceutical Group China, said: "As a pioneer and practitioner of precision diagnosis and treatment of lung cancer, Pfizer has always adhered to the unchanging mission of 'bringing breakthroughs and innovations that change patients' lives', and has made continuous efforts to improve cancer diagnosis and treatment in China.

Group photo of the launching ceremony of Borina(R) listing meeting: Professor Wu Yilong, Honorary Director of Guangdong Lung Cancer Research Institute, Professor Lu Shun, Director of Shanghai Pulmonary Oncology Clinical Medical Center, Chest Hospital Affiliated to Shanghai Jiaotong University, Pfizer Biopharmaceutical Group China Cancer Ms.

In this listing meeting, many well-known experts and scholars in the field of lung cancer diagnosis and treatment at home and abroad gathered together to witness this important moment

In addition, Pfizer simultaneously announced the launch of the "ALK Patient Education Support Program" at the listing meeting to provide Chinese ALK-positive NSCLC patients with comprehensive solutions from consultation to disease management, helping to improve patients' treatment compliance and achieve a more comprehensive survival rate.

The diagnosis and treatment of ALK-positive NSCLC urgently needs to get rid of the dilemma of brain metastasis and acquired drug resistance

The average age of patients with ALK-positive advanced NSCLC is 52 years [1], and they are in the golden period of their youth

In addition, brain metastases are still a nightmare for patients.

Therefore, the main reasons for treatment failure in patients with ALK-positive non-small cell lung cancer are currently brain metastases and acquired drug resistance

Leading ALK-positive NSCLC into a new beginning of 3.

In April this year, the third-generation ALK inhibitor Borrena® was officially approved in China, and the first batch of prescriptions in China were quickly issued in June, which has benefited Chinese patients

Professor Wu Yilong, Honorary Director of Guangdong Lung Cancer Research Institute, said: "According to the clinical research data published by the American Association for Cancer Research (AACR), the median progression-free survival (PFS) of Borrena® in the first-line treatment of ALK-positive NSCLC exceeded three years.

Professor Lu Shun, Director of the Chest Hospital Affiliated to Shanghai Jiaotong University and Director of the Shanghai Pulmonary Oncology Clinical Medical Center, also said: "The benefits of Borrena® to patients are beyond doubt.

ALK patient education support project opens a new model of digital diagnosis and treatment management

The diagnosis and treatment of tumors have brought a heavy burden to the medical field in our country, and have also become a topic of special concern to the country and the government

Cancer treatment has gradually entered a chronic disease management model.

[1]Mitsudomi T, Suda K, Tomizawa K, et al.

[2] Gouji Toyokawa , et al.

[3] Benjamin J.
Solomon, et al.
Updated Efficacy and Safety From the Phase 3 CROWN Study of First-Line Lorlatinib vs Crizotinib in Advanced Anaplastic Lymphoma Kinase (ALK)–Positive Non-Small Cell Lung Cancer (NSCLC).
AACR2022, Abstract #CT223.

Source: Pfizer